The Administrative Core plays a critical organizational role in the success of the SPORE. Dr. Colin Dinney, the Core Director and SPORE Principal Investigator, will facilitate the functioning and interactions of all the projects and the cores. Drs. David McConkey and William Benedict as the Co-Directors of the Administrative Core will co-chair the Executive Committee that is composed of all project Co-Leaders and Core Directors. The SPORE Grant Program Administrator will work closely with Drs. Dinney, McConkey and Benedict to schedule all meetings with investigators and provide timely and effective communication with investigators both within and outside The University of Texas M. D. Anderson Cancer Center. The specific responsibilities of the Administrative Core are: (1) To monitor the research activity of the SPORE;(2) To promote integration and communication between the SPORE and the MD Anderson Multi-disciplinary Research Program in Bladder Cancer (MRP) and the Cancer Center Support (Core) Grant;(3) To monitor scientific integrity and overall compliance with all governmental and NCI regulations and requirements and to coordinate quality assurance including data quality control in conjunction with the Biostatistics and Specimen and Clinical Bioinformatics Core;(4) To provide administrative support for the Developmental Research and Career Development Programs;(5) To convene all necessary meetings, including those of the Executive Committee, Internal Scientific Advisory Committee, and External Scientific Advisory Committee;(6) To oversee expenditures and maintain budget intonation;(7) To communicate and consult frequently with the NCI Project Leader and other staff and prepare all necessary internal and external reports;(9) To establish and maintain electronic communication among all SPORE investigators, including e-mail and a Web page describing SPORE activities, projects, and protocols;(8);To coordinate the activities of the Bladder Cancer Support Team (patient advocacy group);(9) To establish and monitor policies for the recruitment of women and minorities into this program and into any clinical intervention that should arise out of the SPORE;(10) To encourage communication with other groups interested in bladder cancer translational research;(11) To encourage Pharma/Biotech interaction with the SPORE Program.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (O1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Choi, Woonyoung; Porten, Sima; Kim, Seungchan et al. (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152-65
Hoang, Anthony N; Agarwal, Piyush K; Walton-Diaz, Annerleim et al. (2014) Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review. BJU Int 113:E28-33
Benedict, W F; Fisher, M; Zhang, X-Q et al. (2014) Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFN?/Syn3 treatment in a phase l study. Cancer Gene Ther 21:91-4
Figueroa, Jonine D; Ye, Yuanqing; Siddiq, Afshan et al. (2014) Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet 23:1387-98
Culp, Stephen H; Dickstein, Rian J; Grossman, H Barton et al. (2014) Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol 191:40-7
Chakravarti, Deepavali; Su, Xiaohua; Cho, Min Soon et al. (2014) Induced multipotency in adult keratinocytes through down-regulation of ?Np63 or DGCR8. Proc Natl Acad Sci U S A 111:E572-81
Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315-22
Dinney, Colin P N; Hansel, Donna; McConkey, David et al. (2014) Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urol Oncol 32:1108-15
Yan, Chao; Liu, Degang; Li, Liwei et al. (2014) Discovery and characterization of small molecules that target the GTPase Ral. Nature 515:443-7
Lee, Eugene K; Ye, Yuanquing; Kamat, Ashish M et al. (2013) Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer. Cancer 119:1643-51

Showing the most recent 10 out of 178 publications